Evaluation for antiatherogenic efficacy of febuxostat in patients with hyperuricemia

Evaluation for antiatherogenic efficacy of febuxostat in patients with hyperuricemia - Antiatherogenic efficacy of febuxostat

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009134

Enrollment

Registered

2012-11-01

Start date

2012-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperuricemia

Interventions

febuxostat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) serum uric acid levels >7.0mg/dl 2) from 20yr to 84 yr 3) both sexes

Exclusion criteria

Exclusion criteria: 1) known allergic reaction by febuxostat 2) severe renal and/or liver disease 3) pregnant women 4) inadequate candidate at a physician's discretion

Design outcomes

Primary

Measure	Time frame
Improvement of carotid atherosclerosis	—

Secondary

Measure	Time frame
serum uric acid levels	—

Countries

Japan

Contacts

Public ContactKen-ichi Aihara

Department of Medicine and Bioregulatory Sciences First laboratory division

aihara@tokushima-u.ac.jp088-633-7120

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026